2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II—treatments of hypertension

키워드

참고문헌 (97)

1. Lewington S., "Agespecific relevance of usual blood pressure to vascular mortality : a metaanalysis of individual data for one million adults in 61 prospective studies", Lancet, 360, pp.1903~1913 (2002)
2. Julius S., "Feasibility of treating prehypertension with an angiotensin-receptor blocker", N Engl J Med, 354, pp.1685~1697 (2006)
3. Hamada T., "The clinical significance of abnormal diurnal blood pressure variation in healthy late middle-aged and older adults", Blood Press, 17, pp.134~140 (2008)
4. Luders S., "The PHARAO study : prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure : a prospective, randomized, controlled prevention trial of the German Hypertension League", J Hypertens, 26, pp.1487~1496 (2008)
5. Zanchetti A., "When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal", J Hypertens, 27, pp.923~934 (2009)
6. Dagenais GR., "Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose : results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication(DREAM)trial", Diabetes Care, 31, pp.1007~1014 (2008)
7. McMurray JJ., "Effect of valsartan on the incidence of diabetes and cardiovascular events", N Engl J Med, 362, pp.1477~1490 (2010)
8. Schrier RW., "Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes", Kidney Int, 61, pp.1086~1097 (2002)
9. Arima H., "Lower target blood pressures are safe and effective for the prevention of recurrent stroke : the PROGRESS trial", J Hypertens, 24, pp.1201~1208 (2006)
10. Zanchetti A., "How much should blood pressure be lowered? The problem of the J-shaped curve", J Hypertens Suppl, 7, pp.S338~S348 (1989)
11. Zanchetti A., "Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?", J Hypertens, 27, pp.1509~1520 (2009)
12. MRC trial of treatment of mild hypertension : principal results., "Medical Research Council Working Party", Br Med J(Clin Res Ed), 291, pp.97~104 (1985)
13. The Australian therapeutic trial in mild hypertension., "Report by the Management Committee", Lancet, 1, pp.1261~1267 (1980)
14. Collins R., "Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease", Br Med Bull, 50, pp.272~298 (1994)
15. Law MR., "Use of blood pressure lowering drugs in the prevention of cardiovascular disease : meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies", BMJ, 338, pp.b1665~ (2009)
16. Aronow WS., "ACCF", AHA 2011 expert consensus document on hypertension in the elderly : a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension, 2011, pp.57, 2037~2114
17. Liu L., "The Felodipine Event Reduction(FEVER)study : a randomized long-term placebo-controlled trial in Chinese hypertensive patients", J Hypertens, 23, pp.2157~2172 (2005)
18. Zhang Y., "Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial", Eur Heart J, 32, pp.1500~1508 (2011)
19. Beckett NS., "Treatment of hypertension in patients 80 years of age or older", N Engl J Med, 358, pp.1887~1898 (2008)
20. JATOS Study Group., "Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients(JATOS)", Hypertens Res, 31, pp.2115~2127 (2008)
21. Ogihara T., "Target blood pressure for treatment of isolated systolic hypertension in the elderly : valsartan in elderly isolated systolic hypertension study", Hypertension, 56, pp.196~202 (2010)
22. Reboldi G., "Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes : a meta-analysis in 73, 913 patients", J Hypertens, 29, pp.1253~1269 (2011)
23. Cushman WC., "Effects of intensive blood-pressure control in type 2 diabetes mellitus", N Engl J Med, 362, pp.1575~1585 (2010)
24. Hansson L., "Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension : principal results of the hypertension optimal treatment(HOT)randomised trial. HOT Study Group", Lancet, 351, pp.1755~1762 (1998)
25. PATS Collaborating Group., "Poststroke antihypertensive treatment study. A preliminary result", Chin Med J(Engl), 108, pp.8~ (1995)
26. Progress Collaborative Group., "Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack", Lancet, 358, pp.1033~1041 (2001)
27. Rashid P., "Blood pressure reduction and secondary prevention of stroke and other vascular events : a systematic review", Stroke, 34, pp.2741~2748 (2003)
28. Ovbiagele B., "Level of systolic blood pressure within the normal range and risk of recurrent stroke", JAMA, 306, pp.2137~2144 (2011)
29. Yusuf S., "Telmisartan to prevent recurrent stroke and cardiovascular events", N Engl J Med, 359, pp.1225~1237 (2008)
30. Fox KM., "EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease : randomised, double-blind, placebo-controlled, multicentre trial(the EUROPA study)", Lancet, 362, pp.782~788 (2003)
31. Poole-Wilson PA., "Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment(ACTION trial) : randomised controlled trial", Lancet, 364, pp.849~857 (2004)
32. Braunwald E., "Angiotensin-converting-enzyme inhibition in stable coronary artery disease", N Engl J Med, 351, pp.2058~2068 (2004)
33. Klahr S., "The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group", N Engl J Med, 330, pp.877~884 (1994)
34. Wright Jr JT., "Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease : results from the AASK trial", JAMA, 288, pp.2421~2431 (2002)
35. Ruggenenti P., "Blood-pressure control for renoprotection in patients with nondiabetic chronic renal disease(REIN-2) : multicentre, randomised controlled trial", Lancet, 365, pp.939~946 (2005)
36. Sarnak MJ., "The effect of a lower target blood pressure on the progression of kidney disease : long-term follow-up of the modification of diet in renal disease study", Ann Intern Med, 142, pp.342~351 (2005)
37. Appel LJ., "Intensive blood-pressure control in hypertensive chronic kidney disease", N Engl J Med, 363, pp.918~929 (2010)
38. Arguedas JA., "Treatment blood pressure targets for hypertension", Cochrane Database Syst Rev., 8(3), pp.CD004349~ (2009)[DOI]
39. Upadhyay A., "Systematic review : blood pressure target in chronic kidney disease and proteinuria as an effect modifier", Ann Intern Med, 154, pp.541~548 (2011)
40. Mancia G., "2013ESH", ESC Guidelines for the management of arterial hypertension : the Task Force for the management of arterial hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC), 2013, pp.31, 1281~1357
41. Messerli FH., "J curve in hypertension and coronary artery disease", Am J Cardiol, 95, pp.160~ (2005)
42. Elmer PJ., "Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control : 18-month results of a randomized trial", Ann Intern Med, 144, pp.485~495 (2006)
43. 2010 Korean National Health Statistics, "2010 Korean National Health and Nutrition Examination Survey", ~ (2010)
44. Park S., "Association of central hemodynamics with estimated 24-h urinary sodium in patients with hypertension", J Hypertens, 29, pp.1502~1507 (2011)
45. He FJ., "How far should salt intake be reduced?", Hypertension, 42, pp.1093~1099 (2003)
46. Graudal NA., "Effects of low-sodium diet vs. highsodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride(Cochrane review)", Am J Hypertens, 25, pp.1~15 (2012)
47. He FJ., "Nutrition in cardiovascular disease : salt in hypertension and heart failure", Eur Heart J, 32, pp.3073~3080 (2011)
48. Bibbins-Domingo K., "Projected effect of dietary salt reductions on future cardiovascular disease", N Engl J Med, 362, pp.590~599 (2010)
49. He FJ., "Salt reduction lowers cardiovascular risk : metaanalysis of outcome trials", Lancet, 378, pp.380~382 (2011)
50. Taylor RS., "Reduced dietary salt for the prevention of cardiovascular disease : a meta-analysis of randomized controlled trials(Cochrane review)", Am J Hypertens, 24, pp.843~853 (2011)
51. O’Donnell MJ., "Salt intake and cardiovascular disease : why are the data inconsistent?", Eur Heart J, 34, pp.1034~1040 (2013)
52. Whitlock G., "Body-mass index and cause-specific mortality in 900 000 adults : collaborative analyses of 57 prospective studies", Lancet, 373, pp.1083~1096 (2009)
53. Flegal KM., "Association of all-cause mortality with overweight and obesity using standard body mass index categories : a systematic review and meta-analysis", JAMA, 309, pp.71~82 (2013)
54. Jee SH., "Body-mass index and mortality in Korean men and women", N Engl J Med, 355, pp.779~787 (2006)
55. International Association for the Study of Obesity, "The Asia-Pacific Perspective : redefining obesity and its treatment" (2000), West Pacific Region WHO
56. Cornelissen VA., "Impact of resistance training on blood pressure and other cardiovascular risk factors : a metaanalysis of randomized, controlled trials", Hypertension, 58, pp.950~958 (2011)
57. Mann SJ., "Elevation of ambulatory systolic blood pressure in hypertensive smokers. A case–control study", JAMA, 265, pp.2226~2228 (1991)
58. Doll R., "Mortality in relation to smoking : 40 years’ observations on male British doctors", BMJ, 309, pp.901~911 (1994)
59. Appel LJ., "A clinical trial of the effects of dietary patterns on blood pressure, DASH Collaborative Research Group", N Engl J Med, 336, pp.1117~1124 (1997)
60. Obarzanek E., "Effects on blood lipids of a blood pressure-lowering diet : the Dietary Approaches to Stop Hypertension(DASH)Trial", Am J Clin Nutr, 74, pp.80~89 (2001)
61. Sacks FM., "A dietary approach to prevent hypertension : a review of the Dietary Approaches to Stop Hypertension(DASH)Study", Clin Cardiol., 22, pp.III6~III110 (1999)
62. Svetkey LP., "Effects of dietary patterns on blood pressure : subgroup analysis of the Dietary Approaches to Stop Hypertension(DASH)randomized clinical trial", Arch Intern Med, 159, pp.285~293 (1999)
63. Estruch R., "Primary prevention of cardiovascular disease with a Mediterranean diet", N Engl J Med, 368, pp.1279~1290 (2013)
64. Martell N., "Trough to peak ratio of once-daily lisinopril and twice-daily captopril in patients with essential hypertension", J Hum Hypertens, 12, pp.69~72 (1998)
65. Lipicky RJ., "Trough: peak ratio: the rationale behind the United States Food and Drug Administration recommendations", J Hypertens., 12, pp.S17~S18 (1994)
66. Chobanian AV., "Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure", Hypertension, 42, pp.1206~1252 (2003)
67. "Hypertension (CG127):clinical management of primary hypertension in adults"[URL]
68. Elliott WJ., "Incident diabetes in clinical trials of antihypertensive drugs : a network meta-analysis", Lancet, 369, pp.201~207 (2007)
69. Keller KB., "Prinzmetal’s angina", Am J Crit Care, 13, pp.350~354 (2004)
70. Campbell NR., "Canadian Hypertension Education Program : the science supporting New 2011 CHEP recommendations with an emphasis on health advocacy and knowledge translation", Can J Cardiol, 27, pp.407~414 (2011)
71. Bakris GL., "Metabolic effects of carvedilol vs metoprolol in patients with type 2diabetes mellitus and hypertension : a randomized controlled trial", JAMA, 292, pp.2227~2236 (2004)
72. Celik T., "Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients", J Hypertens, 24, pp.591~596 (2006)
73. Zanchetti A., "Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis : principal results of the European Lacidipine Study on Atherosclerosis(ELSA), a randomized, double-blind, long-term trial", Circulation, 106, pp.2422~2427 (2002)
74. Mancia G., "Reappraisal of European guidelines on hypertension management : a European Society of Hypertension Task Force document", J Hypertens, 27, pp.2121~2158 (2009)
75. Brown NJ., "Angiotensin-converting enzyme inhibitors", Circulation, 97, pp.1411~1420 (1998)
76. Palmer BF., "Managing hyperkalemia caused by inhibitors of the reninangiotensin-aldosterone system", N Engl J Med, 351, pp.585~592 (2004)
77. Bicket DP., "Using ACE, inhibitors appropriately", Am Fam Physician, 66, pp.461~468 (2002)
78. Wald DS., "Combination therapy versus monotherapy in reducing blood pressure : meta-analysis on 11, 000participants from 42 trials", Am J Med, 122, pp.290~300 (2009)
79. Patel A., "Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus(the ADVANCE trial) : a randomised controlled trial", Lancet, 370, pp.829~840 (2007)
80. Jamerson K., "Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients", N Engl J Med, 359, pp.2417~2428 (2008)
81. Mann JF., "Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk(the ONTARGET study) : a multicentre, randomised, doubleblind, controlled trial", Lancet, 372, pp.547~553 (2008)
82. Parving HH., "Cardiorenal end points in a trial of aliskiren for type 2 diabetes", N Engl J Med, 367, pp.2204~2213 (2012)
83. Yusuf S., "Telmisartan, ramipril, or both in patients at high risk for vascular events", N Engl J Med, 358, pp.1547~1559 (2008)
84. Persell SD., "Prevalence of resistant hypertension in the United States, 2003–2008", Hypertension, 57, pp.1076~1080 (2011)
85. Zannad F., "Aldosterone antagonist therapy in resistant hypertension", J Hypertens, 25, pp.747~750 (2007)
86. Chapman N., "Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial", Circulation, 118, pp.42~48 (2008)
87. Bobrie G., "Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension : a prospective, randomized, open blinded endpoint study", J Hypertens, 30, pp.1656~1664 (2012)
88. Gaddam KK., "Characterization of resistant hypertension : association between resistant hypertension, aldosterone, and persistent intravascular volume expansion", Arch Intern Med, 168, pp.1159~1164 (2008)
89. Esler MD., "Renal sympathetic denervation in patients with treatment-resistant hypertension(The Symplicity HTN-2 Trial) : a randomised controlled trial", Lancet, 376, pp.1903~1909 (2010)
90. Bhatt DL., "A controlled trial of renal denervation for resistant hypertension", N Engl J Med, 370, pp.1393~1401 (2014)
91. Bisognano JD., "Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension : results from the double-blind, randomized, placebocontrolled rheos pivotal trial", J Am Coll Cardiol, 58, pp.765~773 (2011)
92. Baigent C., "Aspirin in the primary and secondary prevention of vascular disease : collaborative meta-analysis of individual participant data from randomised trials", Lancet, 373, pp.1849~1860 (2009)
93. Jardine MJ., "Aspirin is beneficial in hypertensive patients with chronic kidney disease : a post-hoc subgroup analysis of a randomized controlled trial", J Am Coll Cardiol, 56, pp.956~965 (2010)
94. Ridker PM., "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein", N Engl J Med, 359, pp.2195~2207 (2008)
95. Baigent C., "Cholesterol Treatment Trialists, Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol : a meta-analysis of data from 170, 000participants in 26 randomised trials", Lancet, 376, pp.1670~1681 (2010)
96. Amarenco P., "High-dose atorvastatin after stroke or transient ischemic attack", N Engl J Med, 355, pp.549~559 (2006)
97. Inzucchi SE., "Management of hyperglycaemia in type 2 diabetes : a patient-centered approach. Position statement of the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)", Diabetologia, 55, pp.1577~1596 (2012)

관련 논문AI추천